MAAT PHARMA |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 9.06 EUR | +2.95% |
|
+1.34% | +29.80% |
This article is reserved for members
Already a member?
Log InNot a member ?
Free registration
MaaT Pharma is specialized in the research and development of microbiome biotherapies for use in the treatment of solid cancer tumors.
The company has a portfolio of 2 products in clinical development, including 1 in Phase III (MaaT013 for the treatment of acute graft-versus-host disease) and 1 in Phase IIb (MaaT033 for the prevention of complications of allogeneic hematopoietic stem cell transplantation), and 1 product in preclinical development (MaaT03X for the improvement of the response to immune checkpoint inhibitors in various types of solid tumors).
Calendar
2024-05-13
- Q1 2024 Sales and Revenue Release
Trading Rating
Investor Rating
ESG Refinitiv
Sell
Buy
Mean consensus
BUY
Number of Analysts
3
Last Close Price
9.06
EUR
Average target price
15.5
EUR
Spread / Average Target
+71.08%
EPS Revisions
Annual profits - Rate of surprise
| 1st Jan change | Capi. | |
|---|---|---|
| +29.80% | 109M | |
| -2.26% | 104B | |
| +1.41% | 97.42B | |
| +0.79% | 22.2B | |
| -17.84% | 21.23B | |
| -11.11% | 18.33B | |
| -42.83% | 16.35B | |
| -17.63% | 15.06B | |
| +4.55% | 13.98B | |
| +32.11% | 11.66B |
- Stock Market
- Equities
- MAAT Stock
- News MaaT Pharma
- MaaT Pharma's Immune Disorder Therapy Shows Improved Survival Rate In Clinical Trials
